Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
42 studies found for:    Open Studies | "intraocular melanoma"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "intraocular melanoma"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Stage I Intraocular Melanoma;   Stage IIA Intraocular Melanoma;   Stage IIB Intraocular Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIC Intraocular Melanoma
Interventions: Drug: Sunitinib;   Drug: Valproic Acid
2 Recruiting Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases
Conditions: Iris Melanoma;   Medium/Large Size Posterior Uveal Melanoma;   Stage IIA Uveal Melanoma;   Stage IIB Uveal Melanoma;   Stage IIIA Uveal Melanoma;   Stage IIIB Uveal Melanoma;   Stage IIIC Uveal Melanoma
Interventions: Radiation: External Beam Radiation Therapy;   Other: Laboratory Biomarker Analysis
3 Not yet recruiting Pembrolizumab in Treating Patients With Advanced Uveal Melanoma
Conditions: Stage IIIA Uveal Melanoma;   Stage IIIB Uveal Melanoma;   Stage IIIC Uveal Melanoma;   Stage IV Uveal Melanoma
Interventions: Biological: Pembrolizumab;   Other: Laboratory Biomarker Analysis
4 Unknown  Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye
Condition: Intraocular Melanoma
Interventions: Biological: bevacizumab;   Drug: temozolomide;   Genetic: polymorphism analysis;   Other: pharmacogenomic studies
5 Recruiting Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
Conditions: Extraocular Extension Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma;   Recurrent Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIA Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIB Melanoma;   Stage IIIC Intraocular Melanoma;   Stage IIIC Melanoma;   Stage IV Intraocular Melanoma;   Stage IV Melanoma
Interventions: Drug: axitinib;   Other: laboratory biomarker analysis
6 Not yet recruiting Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
Conditions: Recurrent Uveal Melanoma;   Stage IV Uveal Melanoma
Interventions: Drug: Glembatumumab Vedotin;   Other: Laboratory Biomarker Analysis
7 Recruiting Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
Conditions: Recurrent Uveal Melanoma;   Stage IV Uveal Melanoma
Interventions: Drug: Trametinib;   Drug: Akt Inhibitor GSK2141795;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
8 Recruiting Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma
Condition: Uveal Melanoma
Intervention:
9 Recruiting New Biopsy Technique for Uveal Melanoma
Condition: Uveal Melanoma
Intervention:
10 Recruiting Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients
Condition: Uveal Melanoma
Intervention: Biological: autologous dendritic cells electroporated with mRNA
11 Not yet recruiting Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma
Conditions: Macular Edema;   Cystoid Macular Edema;   Uveal Melanoma;   Radiation Maculopathy;   Radiation Retinopathy
Interventions: Drug: Ozurdex;   Drug: Bevacizumab
12 Recruiting Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
Conditions: Metastatic;   Uveal Melanoma
Interventions: Drug: 75mg selumetinib;   Drug: placebo;   Drug: Dacarbazine
13 Unknown  Study of Circulating Tumoral DNA in Metastatic Choroidal Melanoma
Condition: Choroidal Melanoma, Diffuse
Intervention: Biological: Blood sampling
14 Recruiting BAP1 Testing in Instance Choroidal Nevi or Uveal Melanoma
Condition: Choroidal Nevi, Uveal Melanoma
Intervention:
15 Recruiting Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma
Condition: Uveal Melanoma, Monosomy 3 Positive, no Evidence for Metastases.
Intervention: Biological: Autologous Dendritic Cells loaded with autologous Tumor RNA
16 Recruiting Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Condition: Uveal Melanoma
Intervention: Drug: crizotinib
17 Recruiting Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma
Condition: Uveal Melanoma
Intervention: Radiation: Hypofractionated linear accelerator radiotherapy
18 Recruiting RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
Condition: Uveal Melanoma
Intervention: Drug: RAD001 (Everolimus) and Pasireotide (SOM230) LAR
19 Recruiting A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
Condition: Uveal Melanoma
Interventions: Drug: AEB071;   Drug: MEK162
20 Unknown  Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma
Condition: Intraocular Melanoma
Interventions: Drug: cisplatin;   Drug: sunitinib malate;   Drug: tamoxifen citrate;   Procedure: adjuvant therapy

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years